 Enoxaparin
"Enoxaparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)
| Descriptor ID |
D017984
|
| MeSH Number(s) |
D09.698.373.400.300.200
|
| Concept/Terms |
PK-10,169- PK-10,169
- PK 10,169
- PK10,169
- PK-10169
- PK 10169
- PK10169
|
Below are MeSH descriptors whose meaning is more general than "Enoxaparin".
Below are MeSH descriptors whose meaning is more specific than "Enoxaparin".
This graph shows the total number of publications written about "Enoxaparin" by people in this website by year, and whether "Enoxaparin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2002 | 2 | 0 | 2 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 1 | 2 | | 2016 | 3 | 1 | 4 | | 2017 | 1 | 0 | 1 | | 2018 | 2 | 1 | 3 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Enoxaparin" by people in Profiles.
-
Shah Z, Mastoris I, Acharya P, Rali AS, Mohammed M, Sami F, Ranka S, Wagner S, Zanotti G, Salerno CT, Haglund NA, Sauer AJ, Ravichandran AK, Abicht T. The use of enoxaparin as bridge to therapeutic INR after LVAD implantation. J Cardiothorac Surg. 2020 Nov 14; 15(1):329.
-
Bawa H, Weick JW, Dirschl DR, Luu HH. Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty. J Am Acad Orthop Surg. 2018 Oct 01; 26(19):698-705.
-
Bhatia A, Juricek C, Sarswat N, Adatya S, Kim G, Sayer G, Ota T, Jeevanandam V, Uriel N. Increased Risk of Bleeding in Left Ventricular Assist Device Patients Treated with Enoxaparin as Bridge to Therapeutic International Normalized Ratio. ASAIO J. 2018 Mar/Apr; 64(2):140-146.
-
Dhillon NK, Smith EJT, Gillette E, Mason R, Barmparas G, Gewertz BL, Ley EJ. Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose? Int J Surg. 2018 Mar; 51:128-132.
-
Gibson CM, Korjian S, Chi G, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Lopes RD, Gold A, Cohen AT, Harrington RA. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).
-
Gibson CM, Halaby R, Korjian S, Daaboul Y, Arbetter DF, Yee MK, Goldhaber SZ, Hull R, Hernandez AF, Lu SP, Bandman O, Leeds JM, Gold A, Harrington RA, Cohen AT. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017 Mar; 185:93-100.
-
Gibson CM, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 02 14; 135(7):648-655.
-
Ko A, Harada MY, Barmparas G, Chung K, Mason R, Yim DA, Dhillon N, Margulies DR, Gewertz BL, Ley EJ. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. JAMA Surg. 2016 11 01; 151(11):1006-1013.
-
Pariser JJ, Pearce SM, Anderson BB, Packiam VT, Prachand VN, Smith ND, Steinberg GD. Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin. J Urol. 2017 02; 197(2):302-307.
-
Gonda DD, Fridley J, Ryan SL, Briceño V, Lam SK, Luerssen TG, Jea A. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients. J Neurosurg Pediatr. 2015 Sep; 16(3):329-34.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|